215 related articles for article (PubMed ID: 27580097)
1. Current and potential therapeutic targets of glucagon-like peptide-2.
Austin K; Markovic MA; Brubaker PL
Curr Opin Pharmacol; 2016 Dec; 31():13-18. PubMed ID: 27580097
[TBL] [Abstract][Full Text] [Related]
2. Synergy of glucagon-like peptide-2 and epidermal growth factor coadministration on intestinal adaptation in neonatal piglets with short bowel syndrome.
Lim DW; Levesque CL; Vine DF; Muto M; Koepke JR; Nation PN; Wizzard PR; Li J; Bigam DL; Brubaker PL; Turner JM; Wales PW
Am J Physiol Gastrointest Liver Physiol; 2017 Apr; 312(4):G390-G404. PubMed ID: 28104586
[TBL] [Abstract][Full Text] [Related]
3. HM15912, a Novel Long-Acting Glucagon-Like Peptide-2 Analog, Improves Intestinal Growth and Absorption Capacity in a Male Rat Model of Short Bowel Syndrome.
Choi J; Lee J; Park E; Kwon H; Kim D; Bae S; Choi IY; Kim HH
J Pharmacol Exp Ther; 2023 Feb; 384(2):277-286. PubMed ID: 36410792
[TBL] [Abstract][Full Text] [Related]
4. Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation.
Martin GR; Beck PL; Sigalet DL
World J Gastroenterol; 2006 Jul; 12(26):4117-29. PubMed ID: 16830359
[TBL] [Abstract][Full Text] [Related]
5. Gut adaptation and the glucagon-like peptides.
Drucker DJ
Gut; 2002 Mar; 50(3):428-35. PubMed ID: 11839727
[TBL] [Abstract][Full Text] [Related]
6. Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward?
Yazbeck R; Howarth GS; Abbott CA
Cytokine Growth Factor Rev; 2009 Apr; 20(2):175-84. PubMed ID: 19324585
[TBL] [Abstract][Full Text] [Related]
7. The intestinal epithelial insulin-like growth factor-1 receptor links glucagon-like peptide-2 action to gut barrier function.
Dong CX; Zhao W; Solomon C; Rowland KJ; Ackerley C; Robine S; Holzenberger M; Gonska T; Brubaker PL
Endocrinology; 2014 Feb; 155(2):370-9. PubMed ID: 24265452
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis.
Hu X; Cheng W; Fan S; Huang Y; Chen X; Jiang Z; Wang J
BMC Infect Dis; 2021 Jun; 21(1):583. PubMed ID: 34134659
[TBL] [Abstract][Full Text] [Related]
9. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.
Jeppesen PB; Pertkiewicz M; Forbes A; Pironi L; Gabe SM; Joly F; Messing B; Loth S; Youssef NN; Heinze H; Berghöfer P
Clin Nutr; 2013 Oct; 32(5):713-21. PubMed ID: 23587733
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of intestinal growth and repair by growth factors.
Howarth GS; Shoubridge CA
Curr Opin Pharmacol; 2001 Dec; 1(6):568-74. PubMed ID: 11757811
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of the intestinotropic hormone, glucagon-like peptide-2.
L'Heureux MC; Brubaker PL
Ann Med; 2001 May; 33(4):229-35. PubMed ID: 11405543
[TBL] [Abstract][Full Text] [Related]
12. [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
Otto Buczkowska E; Dworzecki T
Przegl Lek; 2004; 61(9):947-50. PubMed ID: 15803906
[TBL] [Abstract][Full Text] [Related]
13. Differential Effects on Intestinal Adaptation Following Exogenous Glucagon-Like Peptide 2 Therapy With and Without Enteral Nutrition in Neonatal Short Bowel Syndrome [Formula: see text].
Lim DW; Diané A; Muto M; Vine DF; Nation PN; Wizzard PR; Sigalet DL; Bigam DL; Pencharz PB; Turner JM; Wales PW
JPEN J Parenter Enteral Nutr; 2017 Feb; 41(2):156-170. PubMed ID: 27660290
[TBL] [Abstract][Full Text] [Related]
14. A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients.
Naimi RM; Madsen KB; Askov-Hansen C; Brandt CF; Hartmann B; Holst JJ; Mortensen PB; Jeppesen PB
Regul Pept; 2013 Jun; 184():47-53. PubMed ID: 23501043
[TBL] [Abstract][Full Text] [Related]
15. The dual GLP-1 and GLP-2 receptor agonist dapiglutide promotes barrier function in murine short bowel.
Reiner J; Thiery J; Held J; Berlin P; Skarbaliene J; Vollmar B; Jaster R; Eriksson PO; Lamprecht G; Witte M
Ann N Y Acad Sci; 2022 Aug; 1514(1):132-141. PubMed ID: 35580981
[TBL] [Abstract][Full Text] [Related]
16. Is OM-3 synergistic with GLP-2 in intestinal failure?
Karmaker A; Costanzo CM; Schwartz MZ
J Surg Res; 2017 Jan; 207():7-12. PubMed ID: 27979490
[TBL] [Abstract][Full Text] [Related]
17. [Short bowel syndrome. GLP-2 analog teduglutide].
Storr M
Med Monatsschr Pharm; 2013 Sep; 36(9):343-5. PubMed ID: 24069647
[No Abstract] [Full Text] [Related]
18. Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study.
Madsen KB; Askov-Hansen C; Naimi RM; Brandt CF; Hartmann B; Holst JJ; Mortensen PB; Jeppesen PB
Regul Pept; 2013 Jun; 184():30-9. PubMed ID: 23511332
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide 2 and its beneficial effects on gut function and health in production animals.
Connor EE; Evock-Clover CM; Wall EH; Baldwin RL; Santin-Duran M; Elsasser TH; Bravo DM
Domest Anim Endocrinol; 2016 Jul; 56 Suppl():S56-65. PubMed ID: 27345324
[TBL] [Abstract][Full Text] [Related]
20. Short bowel syndrome: the role of GLP-2 on improving outcome.
Wallis K; Walters JR; Gabe S
Curr Opin Clin Nutr Metab Care; 2009 Sep; 12(5):526-32. PubMed ID: 19474717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
